Transverse Abdominis Plane (TAP) Block After Cesarean Delivery
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Since there have been no published dose-response studies investigating the effective
analgesic dose of ropivacaine for use in a TAP block for post-Cesarean delivery analgesia,
the investigators propose a study primarily examining the effect on 24 hour post-Cesarean
delivery opioid consumption of using either a placebo, 0.25% ropivacaine, 0.5% ropivacaine,
or 0.75% ropivacaine for TAP blocks.